Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice

In recent years, sarcopenic obesity has been considered central pathological factors in diabetes. This study aimed to compare the effect of luseogliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), on sarcopenic obesity in comparison to that of a low-carbohydrate diet (LCD). Twenty-week-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hata, Shinnosuke, Okamura, Takuro, Kobayashi, Ayaka, Bamba, Ryo, Miyoshi, Tomoki, Nakajima, Hanako, Kitagawa, Nobuko, Hashimoto, Yoshitaka, Majima, Saori, Senmaru, Takafumi, Okada, Hiroshi, Ushigome, Emi, Nakanishi, Naoko, Takakuwa, Hiroshi, Sasano, Ryoichi, Hamaguchi, Masahide, Fukui, Michiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459736/
https://www.ncbi.nlm.nih.gov/pubmed/36079789
http://dx.doi.org/10.3390/nu14173531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459736/
https://www.ncbi.nlm.nih.gov/pubmed/36079789
http://dx.doi.org/10.3390/nu14173531

Ejemplares similares